MA26994A1 - Quinazolines en tant qu'inhibiteurs de la mmp-13 - Google Patents
Quinazolines en tant qu'inhibiteurs de la mmp-13Info
- Publication number
- MA26994A1 MA26994A1 MA27274A MA27274A MA26994A1 MA 26994 A1 MA26994 A1 MA 26994A1 MA 27274 A MA27274 A MA 27274A MA 27274 A MA27274 A MA 27274A MA 26994 A1 MA26994 A1 MA 26994A1
- Authority
- MA
- Morocco
- Prior art keywords
- quinazolines
- mmp
- inhibitors
- Prior art date
Links
- 102100027995 Collagenase 3 Human genes 0.000 title 1
- 108050005238 Collagenase 3 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26866101P | 2001-02-14 | 2001-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA26994A1 true MA26994A1 (fr) | 2004-12-20 |
Family
ID=23023949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27274A MA26994A1 (fr) | 2001-02-14 | 2003-08-12 | Quinazolines en tant qu'inhibiteurs de la mmp-13 |
Country Status (30)
Country | Link |
---|---|
US (1) | US20020193377A1 (fr) |
EP (1) | EP1368324A1 (fr) |
JP (1) | JP2004523546A (fr) |
KR (1) | KR20030074827A (fr) |
CN (1) | CN1537105A (fr) |
AP (1) | AP2003002841A0 (fr) |
AR (1) | AR032676A1 (fr) |
BG (1) | BG108091A (fr) |
BR (1) | BR0207268A (fr) |
CA (1) | CA2437122A1 (fr) |
CZ (1) | CZ20032142A3 (fr) |
EA (1) | EA200300792A1 (fr) |
EC (1) | ECSP034730A (fr) |
EE (1) | EE200300384A (fr) |
HU (1) | HUP0303164A2 (fr) |
IL (1) | IL157109A0 (fr) |
IS (1) | IS6886A (fr) |
MA (1) | MA26994A1 (fr) |
MX (1) | MXPA03007248A (fr) |
NO (1) | NO20033593L (fr) |
OA (1) | OA12550A (fr) |
PA (1) | PA8539401A1 (fr) |
PE (1) | PE20021005A1 (fr) |
PL (1) | PL367396A1 (fr) |
SK (1) | SK10012003A3 (fr) |
SV (1) | SV2003000876A (fr) |
TN (1) | TNSN03045A1 (fr) |
UY (1) | UY27173A1 (fr) |
WO (1) | WO2002064572A1 (fr) |
ZA (1) | ZA200306008B (fr) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DOP2002000334A (es) * | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz |
PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
MXPA04002537A (es) | 2001-10-12 | 2004-05-31 | Warner Lambert Co | Alquinos como inhibidores de metaloproteinasa de matriz. |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
AU2002249275A1 (en) * | 2002-03-08 | 2003-09-22 | Warner-Lambert Company Llc | Oxo azabicyclic compounds |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
AU2003247024A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
CA2495432A1 (fr) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combinaison d'un inhibiteur carboxylique allosterique de metalloproteinase-13 de matrice et de celecoxibe ou de valdecoxibe |
JP2006503812A (ja) * | 2002-07-17 | 2006-02-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | アロステリックカルボキシルマトリックスメタロプロテイナーゼ−13阻害薬とセレコキシブまたはバルデコキシブではない選択的シクロオキシゲナーゼ−2阻害薬との組み合わせ |
CA2492391A1 (fr) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combinaison d'un inhibiteur allosterique de metalloproteinase matricielle 13 avec un inhibiteur selectif de cyclooxygenase-2, a l'exception du celecoxib ou du valdecoxib |
AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
MXPA05001786A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz. |
AU2003250465A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
WO2004014908A1 (fr) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Inhibiteurs de metalloproteinases heterobicycliques |
AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
AU2003253176A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
MXPA05001785A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de cromona como inhibidores de las metaloproteinasas de matriz. |
WO2004014384A2 (fr) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Composes cycliques contenant des groupes liant le zinc en tant qu'inhibiteurs de metalloprotease de matrice |
AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
WO2004014868A2 (fr) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Derives de pyrimidine 2,4-diones, utilises comme inhibiteurs de metalloproteinase matricielle |
EP1530472A1 (fr) * | 2002-08-13 | 2005-05-18 | Warner-Lambert Company LLC | Derives d'isoquinoleine utilises comme inhibiteurs de metalloprotease de matrice |
WO2004014869A2 (fr) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Derives de 3,4-dihydropyrimidine-2-one 5,6-fondue, utilise comme inhibiteurs de metalloproteinase matricielle |
WO2004014354A1 (fr) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Derives d'uracile fusionnes en 1,6 utilises comme inhibiteurs de metalloproteases matricielles |
JP4859460B2 (ja) * | 2002-12-06 | 2012-01-25 | アフィニウム ファーマシューティカルズ, インク. | ヘテロ環化合物、その製造方法および治療におけるその使用 |
AU2003300114B9 (en) * | 2002-12-31 | 2009-11-26 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatases |
US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
CA2572324A1 (fr) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combinaison d'un inhibiteur allosterique de la metalloproteinase-13 matricielle et d'un ligand au recepteur alpha-2-delta |
WO2005016926A1 (fr) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Derives de pyrido[3,4-d]pyrimidine utiles comme inhibiteurs de la metalloproteinase-13 de matrice |
WO2005019188A1 (fr) * | 2003-08-22 | 2005-03-03 | Takeda Pharmaceutical Company Limited | Derive de pyrimidine fusionne et utilisation associee |
US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
DE10360835A1 (de) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
AP2204A (en) * | 2004-05-06 | 2011-02-07 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides. |
JP5091663B2 (ja) * | 2005-03-16 | 2012-12-05 | 富山化学工業株式会社 | 新規なアントラニル酸誘導体またはその塩 |
EP2054422B1 (fr) | 2006-07-20 | 2017-06-14 | Debiopharm International SA | Dérivés d'acrylamide en tant qu'inhibiteurs de fab i |
EP3255045A1 (fr) | 2007-02-16 | 2017-12-13 | Debiopharm International SA | Sels, promédicaments et polymorphes d'inhibiteurs de fab i |
JP5390407B2 (ja) * | 2007-03-06 | 2014-01-15 | ノバルティス アーゲー | 炎症またはアレルギー症状の処置に適する二環式有機化合物 |
EP3613743B1 (fr) | 2008-01-04 | 2022-03-16 | Intellikine, LLC | Procédés de préparation de dérivés de 1h-pyrazolo[3,4-d]pyrimidin-4-amine |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
BRPI0913119A2 (pt) | 2008-05-27 | 2015-07-28 | Univ Texas | Inibidores de sinalização de proteína wnt |
ES2761173T3 (es) | 2009-05-15 | 2020-05-19 | Univ New York State Res Found | Análogos de curcumina como quelantes de zinc y sus usos |
EP2266984A1 (fr) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pyrido[2,3-d]pyrimidines en tant qu' antagoniste du Wnt pour le traitement du cancer et de l'arthrite |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
TWI659956B (zh) | 2011-01-10 | 2019-05-21 | 美商英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
EP2736330A4 (fr) * | 2011-07-29 | 2015-05-27 | Tempero Pharmaceuticals Inc | Composés et méthodes |
FR2991578B1 (fr) * | 2012-06-06 | 2019-12-27 | L'oreal | Composes pour application anti-age et peau seche |
TR201909016T4 (tr) | 2012-06-19 | 2019-07-22 | Debiopharm Int Sa | (E)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamidin ön ilaç türevleri. |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
ITMI20130646A1 (it) * | 2013-04-19 | 2014-10-20 | Univ Bologna Alma Mater | Composti chinazolindionici con attività inibente sulle sirtuine |
CN103664767A (zh) * | 2013-12-06 | 2014-03-26 | 常熟市联创化学有限公司 | 一种2,6-吡啶二甲酸的制备方法 |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
EP3180340B1 (fr) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Dérivés de pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione |
EP3180345B1 (fr) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Dérivés thieno- et furo[2,3-d]pyrimidine-2,4[1h,3h]-dione en tant que modulateurs trpc5 pour le traitement de maladies neuropsychiatriques |
WO2016023831A1 (fr) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Dérivés de pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione |
EP3180337B1 (fr) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Dérivés de pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione |
WO2016039408A1 (fr) * | 2014-09-11 | 2016-03-17 | 武田薬品工業株式会社 | Composé hétérocyclique |
DK3419628T3 (da) | 2016-02-26 | 2021-01-11 | Debiopharm Int Sa | Medikament til behandling af diabetiske fodinfektioner |
BR112018077021A2 (pt) | 2016-06-24 | 2019-04-02 | Infinity Pharmaceuticals, Inc. | terapias de combinação |
CN111116494B (zh) * | 2019-12-31 | 2022-08-16 | 江苏中旗科技股份有限公司 | 一类含喹唑啉二酮结构的酰胺类化合物、其制备方法与应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU119879A1 (ru) * | 1958-10-21 | 1958-11-30 | В.М. Нестеров | Способ получени 1,3-диметил-4-имино-5,-изонитрозоурацила |
CA764962A (en) * | 1962-03-22 | 1967-08-08 | Ohnacker Gerhard | Pyrido-pyrimidines |
CA762455A (en) * | 1962-03-22 | 1967-07-04 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Pyrido-pyrimidines |
DK408574A (fr) * | 1973-09-06 | 1975-05-05 | Ciba Geigy Ag | |
DE3502590A1 (de) * | 1985-01-26 | 1986-07-31 | Gödecke AG, 1000 Berlin | 5-alkoxy-pyrido(4,3-d)pyrimidin-derivate, verfahren zu deren herstellung und deren verwendung |
DE3502742A1 (de) * | 1985-01-28 | 1986-07-31 | Gödecke AG, 1000 Berlin | 5-oxo-pyrido(4,3-d)pyrimidin-derivate, verfahren zu deren herstellung und deren verwendung |
GB9214053D0 (en) * | 1992-07-02 | 1992-08-12 | Ici Plc | Heterocyclic amides |
ATE181832T1 (de) * | 1993-04-23 | 1999-07-15 | Hoechst Ag | Pyrido-pyrimidindione, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US5281602A (en) * | 1993-04-23 | 1994-01-25 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6-substituted 5,6,7,8-tetrahydro-pyrido[4,3-D]pyrimidin-4(3H)-ones |
ES2153975T3 (es) * | 1995-08-02 | 2001-03-16 | Uriach & Cia Sa J | Derivados de pirimidona con actividad antifungica. |
HRP970244B1 (en) * | 1996-05-15 | 2005-06-30 | Bayer Corporation | Inhibition of matrix metalloproteases by 2-substit |
US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
NZ334897A (en) * | 1996-12-09 | 2001-02-23 | Warner Lambert Co | Medicaments for treating and preventing heart failure and ventricular dilatation |
AU4429799A (en) * | 1998-06-12 | 1999-12-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
US20030114666A1 (en) * | 2001-06-19 | 2003-06-19 | Ellsworth Edmund Lee | Antibacterial agents |
WO2003103575A2 (fr) * | 2002-05-23 | 2003-12-18 | Cytokinetics, Inc. | Composes, compositions et procedes |
AU2003281168A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
CA2495432A1 (fr) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combinaison d'un inhibiteur carboxylique allosterique de metalloproteinase-13 de matrice et de celecoxibe ou de valdecoxibe |
AU2003249505A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
JP2006503812A (ja) * | 2002-07-17 | 2006-02-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | アロステリックカルボキシルマトリックスメタロプロテイナーゼ−13阻害薬とセレコキシブまたはバルデコキシブではない選択的シクロオキシゲナーゼ−2阻害薬との組み合わせ |
MXPA05001642A (es) * | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de naftaleno como inhibidores de metaloproteinasas de matriz. |
MXPA05001785A (es) * | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de cromona como inhibidores de las metaloproteinasas de matriz. |
WO2004014869A2 (fr) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Derives de 3,4-dihydropyrimidine-2-one 5,6-fondue, utilise comme inhibiteurs de metalloproteinase matricielle |
AU2003249534A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors |
AU2003250465A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
AU2003253149A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors |
EP1530472A1 (fr) * | 2002-08-13 | 2005-05-18 | Warner-Lambert Company LLC | Derives d'isoquinoleine utilises comme inhibiteurs de metalloprotease de matrice |
WO2004014354A1 (fr) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Derives d'uracile fusionnes en 1,6 utilises comme inhibiteurs de metalloproteases matricielles |
AU2003250466A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
US7439249B2 (en) * | 2002-12-31 | 2008-10-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatases |
US7625909B2 (en) * | 2003-05-23 | 2009-12-01 | Novartis Vaccines And Diagnostics, Inc. | Substituted quinazolinone compounds |
CA2537325A1 (fr) * | 2003-09-19 | 2005-03-31 | Gilead Sciences, Inc. | Composes d'aza-quinolinol phosphonate inhibiteurs de l'integrase |
-
2002
- 2002-02-08 PA PA20028539401A patent/PA8539401A1/es unknown
- 2002-02-11 EP EP02722137A patent/EP1368324A1/fr not_active Withdrawn
- 2002-02-11 MX MXPA03007248A patent/MXPA03007248A/es unknown
- 2002-02-11 KR KR10-2003-7010659A patent/KR20030074827A/ko not_active Application Discontinuation
- 2002-02-11 WO PCT/EP2002/001979 patent/WO2002064572A1/fr not_active Application Discontinuation
- 2002-02-11 EE EEP200300384A patent/EE200300384A/xx unknown
- 2002-02-11 JP JP2002564505A patent/JP2004523546A/ja not_active Abandoned
- 2002-02-11 CZ CZ20032142A patent/CZ20032142A3/cs unknown
- 2002-02-11 BR BR0207268-8A patent/BR0207268A/pt not_active IP Right Cessation
- 2002-02-11 CN CNA028050142A patent/CN1537105A/zh active Pending
- 2002-02-11 CA CA002437122A patent/CA2437122A1/fr not_active Abandoned
- 2002-02-11 AP APAP/P/2003/002841A patent/AP2003002841A0/en unknown
- 2002-02-11 OA OA1200300200A patent/OA12550A/en unknown
- 2002-02-11 PL PL02367396A patent/PL367396A1/xx not_active Application Discontinuation
- 2002-02-11 HU HU0303164A patent/HUP0303164A2/hu unknown
- 2002-02-11 IL IL15710902A patent/IL157109A0/xx unknown
- 2002-02-11 SK SK1001-2003A patent/SK10012003A3/sk unknown
- 2002-02-11 EA EA200300792A patent/EA200300792A1/ru unknown
- 2002-02-13 US US10/075,954 patent/US20020193377A1/en not_active Abandoned
- 2002-02-13 PE PE2002000118A patent/PE20021005A1/es not_active Application Discontinuation
- 2002-02-13 SV SV2002000876A patent/SV2003000876A/es not_active Application Discontinuation
- 2002-02-13 AR ARP020100470A patent/AR032676A1/es not_active Application Discontinuation
- 2002-02-13 UY UY27173A patent/UY27173A1/es not_active Application Discontinuation
-
2003
- 2003-07-08 TN TNPCT/EP2002/001979A patent/TNSN03045A1/fr unknown
- 2003-07-24 IS IS6886A patent/IS6886A/is unknown
- 2003-08-04 ZA ZA2003/06008A patent/ZA200306008B/en unknown
- 2003-08-12 MA MA27274A patent/MA26994A1/fr unknown
- 2003-08-13 NO NO20033593A patent/NO20033593L/no not_active Application Discontinuation
- 2003-08-13 EC EC2003004730A patent/ECSP034730A/es unknown
- 2003-08-13 BG BG108091A patent/BG108091A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20020193377A1 (en) | 2002-12-19 |
CZ20032142A3 (cs) | 2004-12-15 |
AR032676A1 (es) | 2003-11-19 |
KR20030074827A (ko) | 2003-09-19 |
PA8539401A1 (es) | 2002-10-28 |
PL367396A1 (en) | 2005-02-21 |
BG108091A (en) | 2004-12-30 |
CA2437122A1 (fr) | 2002-08-22 |
WO2002064572A1 (fr) | 2002-08-22 |
CN1537105A (zh) | 2004-10-13 |
IS6886A (is) | 2003-07-24 |
MXPA03007248A (es) | 2005-02-14 |
ZA200306008B (en) | 2005-01-26 |
ECSP034730A (es) | 2003-12-01 |
AP2003002841A0 (en) | 2003-09-30 |
EE200300384A (et) | 2003-12-15 |
NO20033593D0 (no) | 2003-08-13 |
EP1368324A1 (fr) | 2003-12-10 |
EA200300792A1 (ru) | 2004-02-26 |
UY27173A1 (es) | 2002-09-30 |
BR0207268A (pt) | 2005-03-15 |
SK10012003A3 (sk) | 2004-09-08 |
IL157109A0 (en) | 2004-02-08 |
PE20021005A1 (es) | 2002-11-27 |
HUP0303164A2 (hu) | 2004-01-28 |
NO20033593L (no) | 2003-08-13 |
SV2003000876A (es) | 2003-08-19 |
OA12550A (en) | 2006-06-05 |
JP2004523546A (ja) | 2004-08-05 |
TNSN03045A1 (fr) | 2005-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA26994A1 (fr) | Quinazolines en tant qu'inhibiteurs de la mmp-13 | |
FR20C1039I2 (fr) | Derives de l'uk-2a | |
FR15C0086I2 (fr) | Derives d'hydroxamate en tant qu'inhibiteurs de desacetylase | |
MA27126A1 (fr) | 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES | |
MA26812A1 (fr) | Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases | |
DZ3425A1 (fr) | Derives de quinolinone en tant qu'inhibiteurs kinases de tyrosine | |
FR2829142B1 (fr) | Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues | |
FR2816843B1 (fr) | Inhibiteurs de l'enzyme 5 alpha-reductase | |
FR2820471B3 (fr) | Perfectionnement apporte a la structure d'une vis | |
NO20041968L (no) | Anvendelse av cystationin | |
FR2824092B1 (fr) | Ensemble d'elements de construction | |
ATE309994T1 (de) | Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten | |
NO20031267D0 (no) | 4-aminokinazoliner | |
ITMI20010859A0 (it) | Procedimento integrato per la produzione di ossidi olefinici | |
DE60031450D1 (de) | Polymorph v von torasemid | |
MA27240A1 (fr) | Derives d'imidazoquinoleine | |
MA27140A1 (fr) | Les oligopeptides et les compositions qui les contiennent en tant qu'inhibiteurs de cathepsin s | |
ITMI20011132A0 (it) | Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico | |
PT1392670E (pt) | Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina | |
FR2821553B1 (fr) | Utilisation d'un ou plusieurs shogaol (s) en tant qu'aphrodisiaque | |
ATE331956T1 (de) | Nachweis von entzündungen | |
MA26966A1 (fr) | Nouveaux composes utilisables en tant qu'inhibiteurs de protease hiv | |
ITMI20011833A0 (it) | Agenti che regolano la permeabilita' vascolare | |
DE60207900D1 (de) | "Suspend"-Paketübertrager | |
ITMI20020158A0 (it) | Procedimento atto all'individuazione di incendi |